Download PDF
Pharmacopsychiatry 2018; 51(06): 270-271
DOI: 10.1055/s-0043-122603
Letter to the Editor
© Georg Thieme Verlag KG Stuttgart · New York

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

Sara Baldelli
1   Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
,
Emilio Clementi
2   Clinical Pharmacology Unit, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Department of Biomedical and Clinical Sciences L. Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
3   E. Medea Scientific Institute, Bosisio Parini, Italy
,
Dario Cattaneo
1   Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
› Author Affiliations
Further Information

Publication History

received 16 October 2017
revised 26 October 2017

accepted 07 November 2017

Publication Date:
27 November 2017 (online)

Also available at
    Permissions and Reprints

Abstract

The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines.

 

  • References

  • 1 Hiemke C, Bergemann N. Clement et al. Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Sreeraj VS, Shivakumar V, Rao NP. et al. A critical appraisal of long acting injectable antipsychotics: Translating research to clinics. Asian J Psychiatr 2017; 28: 57-64
    CrossrefPubMedGoogle Scholar
  • 3 Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: A narrative review and critical appraisal. Expert Opin Drug Deliv. 2016; 13: 253-264
    CrossrefPubMedGoogle Scholar
  • 4 Biagi E, Capuzzi E, Colmegna F. et al. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Adv Ther 2017; 34: 1036-1048
    CrossrefPubMedGoogle Scholar
  • 5 Mohr P, Knytl P, Voráčková V et al. Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. Int J Clin Pract. 2017; 71:
    PubMed
  • 6 Baldelli S, Fucile S, Cattaneo D. et al. Development of a LC-MS/MS method for therapeutic drug monitoring of antidepressants and antipsychotics in human plasma. Ther Drug Monit 2011; 33: 528
    PubMedGoogle Scholar
  • 7 Pozzi M, Cattaneo D, Baldelli S. et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol. 2016; 72: 285-293
    CrossrefPubMedGoogle Scholar
  • 8 Schoretsanitis G, Spina E, Hiemke C. et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 2017; 10: 965-981
    CrossrefPubMedGoogle Scholar